Eikon Therapeutics

The NYSE joined us in celebrating Eikon’s $350.7M Series D financing announcement with a trading floor takeover! As we continue advancing our clinical pipeline and expanding our research, we’re grateful for the confidence of our investors and the dedication of #TeamEikon in pushing the boundaries of drug discovery. A big thank you to the NYSE for marking this pivotal milestone with us. Check out some highlights from the trading floor. 👇

We’re excited to announce the initial close of $350.7 million in new financing, bringing our privately raised total to more than $1.1 billion since Eikon was founded in 2019. This investment further fuels our mission to develop transformative medicines for grievous illnesses. With clinical studies now running in 28 countries across 5 continents, we are accelerating the development of much-needed therapies while continuing to expand our research and development capabilities. “This financing provides the resources necessary to build a fully-integrated, 21st-century biotechnology company that leverages advanced computing, data sciences, and decades of experience in bringing innovative medicines to patients. The continued support of our world-class syndicate of investors is a testament both to the progress we have already made, and to the confidence of investors in our ability to deliver important new medicines for the world," said Eikon CEO and Board Chair Roger M. Perlmutter, M.D., Ph.D. in today’s announcement. We’re grateful for the continued support of our investors and the continued dedication of #TeamEikon. Learn more: https://lnkd.in/gPKhDcBe #DrugDiscovery #Biotech #Biopharma #FutureofBiotech

#TeamEikon is heading to Boston next week for the 45th Annual TD Cowen Health Care Conference, March 3-5! We’re looking forward to engaging with the life sciences investment community and sharing a number of exciting updates on our pipeline and clinical progress.  

Eikon Therapeutics is looking forward to presenting at the annual J.P. Morgan Healthcare Conference next week in San Francisco. On Monday, January 13, at 9 am PST, CEO and Board Chair Roger M. Perlmutter, M.D., Ph.D., will provide a business update highlighting recent clinical development progress as well as important advances in Eikon’s research programs.    We hope to see you there!   #JPM2025 #JPM25 #DrugDiscovery #Biotech #Therapeutics

We’re excited to announce the launch of our new website! The redesigned site reflects our progress toward advancing breakthrough therapeutics through the purposeful integration of science and engineering. With the power of live-cell imaging, proprietary technologies, and data science, Eikon’s interdisciplinary team is uncovering new drug candidates and accelerating the path from research to treatment so we can deliver new medicines that address serious illnesses. What you’ll find: ➡️ Insights into our proprietary technologies including our pioneering single-molecule tracking (SMT) platform ➡️Published papers and resources on our novel research ➡️Opportunities to join our growing team with East and West Coast openings We invite you to explore and connect with us as we push the boundaries of science. Visit us at: www.eikontx.com. #DrugDiscovery #Biotech #Therapeutics #TeamEikon

We are pleased to announce that Michael Klobuchar is joining Eikon Therapeutics as our new Chief Operating Officer! Mike joins Eikon from Merck & Co. Inc. where he spent more than 25 years in senior leadership roles across R&D, manufacturing, finance, and corporate strategy, most recently as Executive Vice President & Chief Strategy Officer. “Mike is an outstanding leader whose deep experience in navigating complex industrial strategies and his proven track record of operational excellence make him the ideal person to lead Eikon’s infrastructure development as we scale our efforts to bring transformative discovery technologies to scientists and innovative new therapies to patients,” said Eikon CEO & Board Chair Roger M. Perlmutter, M.D., Ph.D. At Eikon, we are dedicated to advancing our pioneering single-molecule tracking (SMT) platform to develop next-generation therapeutics. As we continue to scale and push the boundaries of what’s possible, Mike will play a pivotal role in driving our operational excellence and strategic growth, ensuring that Eikon remains at the forefront of scientific discovery and patient impact. Learn more here: https://lnkd.in/gxUbJ-KD Please join us in welcoming Mike to #TeamEikon!

We're excited to see this collaborative work from the Tim Mitchison and Pamela Silver labs at Harvard Medical School posted on biorXiv. At Eikon, we’ve seen how measuring the movement of proteins in the cell can be a powerful and versatile tool for drug discovery. By participating in Eikon's Technology Access Program, Rui Tong Quek was able to measure protein-protein interactions with our single-molecule tracking (SMT) platform in support of her research on condensate formation. Eikon’s SMT platform permits us to assay protein motion in live cells by measuring the movement of millions of individual proteins. Using Eikon’s high-throughput platform, Rui measured the condensate formation of nucleocapsid (N) protein from SARS-CoV-2. Not only could she measure changes in N-protein motion upon GSK3 inhibition, but she could also see those changes starting to occur within an hour, well before any sort of condensates become visible. Check out the preprint or learn more: https://lnkd.in/gJupmUys #DrugDiscovery #SingleMoleculeTracking #SMT 

Our team at Eikon Therapeutics is making waves in drug discovery by leveraging cutting-edge AI technologies. Eikon Associate Director Adi Hanuka, PhD, recently presented how our advanced AI models are overcoming challenges in predicting drug absorption. By integrating public and proprietary data, our models are significantly improving prediction accuracy, leading to faster and more effective drug development. Excited about the future? We are too! Stay tuned for more groundbreaking advancements from our talented team. #TeamEikon #AI #DrugDiscovery #BiotechInnovation

At Eikon Therapeutics, our Clinical team plays a vital role in translating groundbreaking discoveries into life-changing medicines for patients with unmet needs, including cancer and neurodegenerative diseases. With a commitment to patient-centered clinical excellence, we prioritize the well-being of participants in our clinical trials and strive to deliver high-quality data that supports the development of effective therapies. Our track record showcases our integrated capabilities to advance both in-licensed assets and those emerging from our proprietary platform. As part of #TeamEikon, you'll contribute to a vision that redefines the boundaries of science, driving innovation that has the potential to transform the lives of patients around the world. Explore West- and East-Coast opportunities to join our clinical team here: https://lnkd.in/g7V6b9RZ #ClinicalResearch #HealthcareInnovation #ScienceCareers

Navigating the complexities of clinical trial supply chains is more challenging than ever as the industry adapts to new technologies and ever-changing global regulations. On September 17, Eikon Therapeutics’ Senior Director of Clinical Supply Chain Reid Tonik will share insights on “Creating a Clinical Supply Chain Playbook for Onboarding Acquired Assets” at Clinical Trial Supply West Coast in San Francisco. Reid will cover best practices and actionable strategies including: ➡ Identifying priorities and guiding transition activities while mitigating risks to patient dosing and trial continuity in a culturally and personally mindful way. ➡ Deciding when and what to integrate, and assessing the impact on the acquired portfolio. ➡ Tools of the trade and lessons learned from past mistakes. We hope to see you there!   #TeamEikon #ClinicalTrials #ClinicalOperations #CTSWestCoast